BridgeMD
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post COVID-19 Condition
EU CTIS ID: 2023-504087-42-00
What this study is testing
To compare plitidepsin 2.5 mg vs placebo in terms of improvement of functional status in patients with post COVID-19 condition (PCC).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female individuals 18 years old or older.
- Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test [polymerase chain reaction (PCR) or transcription mediated amplification (TMA)], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) positive serology against SARS-CoV-2 N protein regardless vaccination status.
- Symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot explained by an alternative diagnosis
- Unable to perform all usual duties/activities, defined as grades 3 or 4 in PCFS.
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- Having understood the information provided and capable of providing informed consent.
You likely can't join if
- Last SARS-CoV-2 vaccine dose during the previous 30 days.
- Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.
- Pacients receiving chronic glucocorticoid therapy
- Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin.
- Unable to consent and/or comply with study requirements, in the opinion of the investigator.
- Currently participating or participated in a clinical trial within the prior 30 days, or a planned participation in any other clinical trial within the next 90 days.
See the full eligibility criteria
Who can join
- Male or female individuals 18 years old or older.
- Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test [polymerase chain reaction (PCR) or transcription mediated amplification (TMA)], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) positive serology against SARS-CoV-2 N protein regardless vaccination status.
- Symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot explained by an alternative diagnosis
- Unable to perform all usual duties/activities, defined as grades 3 or 4 in PCFS.
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- Having understood the information provided and capable of providing informed consent.
What rules you out
- Last SARS-CoV-2 vaccine dose during the previous 30 days.
- Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.
- Pacients receiving chronic glucocorticoid therapy
- Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin.
- Unable to consent and/or comply with study requirements, in the opinion of the investigator.
- Currently participating or participated in a clinical trial within the prior 30 days, or a planned participation in any other clinical trial within the next 90 days.
- Patients with active uncontrolled infections.
- Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers throughout plitidepsin treatment period and until 24-h washout period.
- Any of the following cardiac conditions or risk factors: 1. Cardiac infarction or cardiac surgery episode within the last six months; 2. History of known congenital QT prolongation; 3. Known structural cardiomyopathy with abnormal LVEF (<50%); 4. Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).
- Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive systemic glucocorticoids, antihistamine H1/H2 receptor agents, or antiserotonine 5HT3 receptors drugs.
- Mast cell activation syndrome
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.